Pieris Pharmaceuticals (PIRS) Rating Lowered to Sell at BidaskClub

Pieris Pharmaceuticals (NASDAQ:PIRS) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a report issued on Wednesday.

Other analysts have also issued reports about the stock. HC Wainwright set a $12.00 price target on shares of Pieris Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, February 9th. ValuEngine upgraded shares of Pieris Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. William Blair assumed coverage on shares of Pieris Pharmaceuticals in a report on Wednesday, January 17th. They issued an “outperform” rating on the stock. Evercore ISI assumed coverage on shares of Pieris Pharmaceuticals in a report on Monday, March 19th. They issued an “outperform” rating and a $13.00 price objective on the stock. Finally, Jefferies Group assumed coverage on shares of Pieris Pharmaceuticals in a report on Monday, March 19th. They issued a “buy” rating and a $12.00 price objective on the stock. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. Pieris Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $11.00.

How to Become a New Pot Stock Millionaire

NASDAQ PIRS opened at $6.56 on Wednesday. Pieris Pharmaceuticals has a 1 year low of $2.26 and a 1 year high of $9.75.

Pieris Pharmaceuticals (NASDAQ:PIRS) last posted its quarterly earnings results on Friday, March 9th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.04) by $0.21. Pieris Pharmaceuticals had a negative net margin of 69.82% and a negative return on equity of 162.54%. The firm had revenue of $18.15 million for the quarter, compared to analyst estimates of $7.63 million. equities research analysts forecast that Pieris Pharmaceuticals will post -0.53 earnings per share for the current year.

In other Pieris Pharmaceuticals news, major shareholder Orbimed Advisors Llc sold 7,897 shares of the company’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $8.98, for a total value of $70,915.06. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 4.05% of the stock is owned by insiders.

Several hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. grew its stake in shares of Pieris Pharmaceuticals by 4.4% in the fourth quarter. BlackRock Inc. now owns 1,596,382 shares of the biotechnology company’s stock valued at $12,053,000 after acquiring an additional 67,895 shares in the last quarter. Millennium Management LLC grew its stake in shares of Pieris Pharmaceuticals by 57.9% in the fourth quarter. Millennium Management LLC now owns 699,771 shares of the biotechnology company’s stock valued at $5,283,000 after acquiring an additional 256,622 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Pieris Pharmaceuticals by 63.7% in the fourth quarter. Renaissance Technologies LLC now owns 650,100 shares of the biotechnology company’s stock valued at $4,908,000 after acquiring an additional 253,000 shares in the last quarter. State Street Corp acquired a new position in shares of Pieris Pharmaceuticals in the second quarter valued at about $2,377,000. Finally, Arrowstreet Capital Limited Partnership acquired a new position in shares of Pieris Pharmaceuticals in the fourth quarter valued at about $3,370,000. Institutional investors and hedge funds own 43.99% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.tickerreport.com/banking-finance/3334909/pieris-pharmaceuticals-pirs-rating-lowered-to-sell-at-bidaskclub.html.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Analyst Recommendations for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Brokers Set Expectations for Signature Bank’s Q2 2018 Earnings
Brokers Set Expectations for Signature Bank’s Q2 2018 Earnings
Northfield Bancorp  Scheduled to Post Quarterly Earnings on Tuesday
Northfield Bancorp Scheduled to Post Quarterly Earnings on Tuesday
Volaris  Stock Rating Lowered by ValuEngine
Volaris Stock Rating Lowered by ValuEngine
Pool  Stock Rating Lowered by ValuEngine
Pool Stock Rating Lowered by ValuEngine
ValuEngine Downgrades Lumber Liquidators  to Strong Sell
ValuEngine Downgrades Lumber Liquidators to Strong Sell
ValuEngine Downgrades Goldman Sachs  to Hold
ValuEngine Downgrades Goldman Sachs to Hold


© 2006-2018 Ticker Report. Google+.